nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—Angiotensin 2 Receptor Antagonists—Telmisartan—coronary artery disease	0.142	0.541	CiPCiCtD
Valsartan—type 2 diabetes mellitus—coronary artery disease	0.137	1	CtDrD
Valsartan—Angiotensin 2 Receptor Antagonists—Losartan—coronary artery disease	0.121	0.46	CiPCiCtD
Valsartan—Olmesartan—coronary artery disease	0.109	0.552	CrCtD
Valsartan—Losartan—coronary artery disease	0.0883	0.448	CrCtD
Valsartan—AGTR1—coronary artery disease	0.0614	0.809	CbGaD
Valsartan—AGTR1—Olmesartan—coronary artery disease	0.019	0.137	CbGbCtD
Valsartan—AGTR1—Telmisartan—coronary artery disease	0.0152	0.11	CbGbCtD
Valsartan—ALB—coronary artery disease	0.0145	0.191	CbGaD
Valsartan—Irbesartan—Olmesartan—coronary artery disease	0.0129	0.0959	CrCrCtD
Valsartan—Forasartan—Olmesartan—coronary artery disease	0.0129	0.0959	CrCrCtD
Valsartan—Olmesartan—Telmisartan—coronary artery disease	0.0124	0.0919	CrCrCtD
Valsartan—Tasosartan—Olmesartan—coronary artery disease	0.0114	0.0847	CrCrCtD
Valsartan—Losartan—Telmisartan—coronary artery disease	0.0113	0.0836	CrCrCtD
Valsartan—Irbesartan—Losartan—coronary artery disease	0.0105	0.0778	CrCrCtD
Valsartan—Forasartan—Losartan—coronary artery disease	0.0105	0.0778	CrCrCtD
Valsartan—Candesartan—Telmisartan—coronary artery disease	0.0104	0.0769	CrCrCtD
Valsartan—Losartan—Olmesartan—coronary artery disease	0.00934	0.0693	CrCrCtD
Valsartan—Tasosartan—Losartan—coronary artery disease	0.00927	0.0687	CrCrCtD
Valsartan—SLCO1B3—Olmesartan—coronary artery disease	0.00877	0.0632	CbGbCtD
Valsartan—Candesartan—Olmesartan—coronary artery disease	0.00859	0.0637	CrCrCtD
Valsartan—AGTR1—Losartan—coronary artery disease	0.00851	0.0614	CbGbCtD
Valsartan—Olmesartan—Losartan—coronary artery disease	0.00833	0.0618	CrCrCtD
Valsartan—SLCO1B3—Pitavastatin—coronary artery disease	0.00701	0.0506	CbGbCtD
Valsartan—SLCO1B3—Telmisartan—coronary artery disease	0.00701	0.0506	CbGbCtD
Valsartan—Candesartan—Losartan—coronary artery disease	0.00697	0.0517	CrCrCtD
Valsartan—SLCO1B1—Gemfibrozil—coronary artery disease	0.00539	0.0389	CbGbCtD
Valsartan—SLCO1B3—Rosuvastatin—coronary artery disease	0.00517	0.0373	CbGbCtD
Valsartan—SLCO1B1—Olmesartan—coronary artery disease	0.00511	0.0368	CbGbCtD
Valsartan—SLCO1B3—Pravastatin—coronary artery disease	0.0047	0.0339	CbGbCtD
Valsartan—SLCO1B3—Atorvastatin—coronary artery disease	0.00428	0.0309	CbGbCtD
Valsartan—SLCO1B1—Pitavastatin—coronary artery disease	0.00408	0.0294	CbGbCtD
Valsartan—SLCO1B3—Losartan—coronary artery disease	0.00392	0.0282	CbGbCtD
Valsartan—SLCO1B1—Rosuvastatin—coronary artery disease	0.00301	0.0217	CbGbCtD
Valsartan—SLCO1B1—Ezetimibe—coronary artery disease	0.00301	0.0217	CbGbCtD
Valsartan—SLCO1B1—Simvastatin—coronary artery disease	0.0028	0.0202	CbGbCtD
Valsartan—SLCO1B1—Lovastatin—coronary artery disease	0.00274	0.0198	CbGbCtD
Valsartan—SLCO1B1—Pravastatin—coronary artery disease	0.00274	0.0198	CbGbCtD
Valsartan—SLCO1B1—Atorvastatin—coronary artery disease	0.00249	0.018	CbGbCtD
Valsartan—SLCO1B1—Losartan—coronary artery disease	0.00228	0.0165	CbGbCtD
Valsartan—ALB—Pitavastatin—coronary artery disease	0.00224	0.0161	CbGbCtD
Valsartan—CYP2C9—Fenofibrate—coronary artery disease	0.00199	0.0143	CbGbCtD
Valsartan—ALB—Rosuvastatin—coronary artery disease	0.00165	0.0119	CbGbCtD
Valsartan—ALB—Acetylsalicylic acid—coronary artery disease	0.00161	0.0116	CbGbCtD
Valsartan—CYP2C9—Gemfibrozil—coronary artery disease	0.00159	0.0115	CbGbCtD
Valsartan—ALB—Captopril—coronary artery disease	0.00159	0.0114	CbGbCtD
Valsartan—CYP2C9—Clopidogrel—coronary artery disease	0.00138	0.00994	CbGbCtD
Valsartan—ALB—Furosemide—coronary artery disease	0.00128	0.0092	CbGbCtD
Valsartan—CYP2C9—cardial valve—coronary artery disease	0.00126	0.379	CbGeAlD
Valsartan—ALB—Losartan—coronary artery disease	0.00125	0.00901	CbGbCtD
Valsartan—CYP2C9—Pitavastatin—coronary artery disease	0.00121	0.00869	CbGbCtD
Valsartan—CYP2C9—Rosuvastatin—coronary artery disease	0.000888	0.00641	CbGbCtD
Valsartan—CYP2C9—Acetylsalicylic acid—coronary artery disease	0.000866	0.00624	CbGbCtD
Valsartan—CYP2C9—Simvastatin—coronary artery disease	0.000826	0.00596	CbGbCtD
Valsartan—CYP2C9—Pravastatin—coronary artery disease	0.000808	0.00583	CbGbCtD
Valsartan—CYP2C9—Lovastatin—coronary artery disease	0.000808	0.00583	CbGbCtD
Valsartan—CYP2C9—Atorvastatin—coronary artery disease	0.000736	0.00531	CbGbCtD
Valsartan—CYP2C9—Losartan—coronary artery disease	0.000673	0.00486	CbGbCtD
Valsartan—AGTR1—artery—coronary artery disease	0.000393	0.118	CbGeAlD
Valsartan—AGTR1—endothelium—coronary artery disease	0.000332	0.0997	CbGeAlD
Valsartan—AGTR1—cardiac ventricle—coronary artery disease	0.000221	0.0662	CbGeAlD
Valsartan—AGTR1—myocardium—coronary artery disease	0.000208	0.0623	CbGeAlD
Valsartan—Forasartan—AGTR1—coronary artery disease	0.0002	0.245	CrCbGaD
Valsartan—AGTR1—heart—coronary artery disease	0.000145	0.0435	CbGeAlD
Valsartan—AGTR1—cardiovascular system—coronary artery disease	0.000137	0.041	CbGeAlD
Valsartan—AGTR1—cardiac atrium—coronary artery disease	0.000124	0.0372	CbGeAlD
Valsartan—Tasosartan—AGTR1—coronary artery disease	0.000121	0.148	CrCbGaD
Valsartan—Irbesartan—EDNRA—coronary artery disease	0.000119	0.146	CrCbGaD
Valsartan—ALB—heart—coronary artery disease	0.000112	0.0335	CbGeAlD
Valsartan—AGTR1—blood—coronary artery disease	0.000108	0.0324	CbGeAlD
Valsartan—SLCO1B1—blood—coronary artery disease	0.000103	0.0309	CbGeAlD
Valsartan—Olmesartan—AGTR1—coronary artery disease	0.000102	0.125	CrCbGaD
Valsartan—Candesartan—AGTR1—coronary artery disease	7.95e-05	0.0975	CrCbGaD
Valsartan—Irbesartan—AGTR1—coronary artery disease	7.95e-05	0.0975	CrCbGaD
Valsartan—CYP2C9—heart—coronary artery disease	6.98e-05	0.0209	CbGeAlD
Valsartan—CYP2C9—cardiovascular system—coronary artery disease	6.58e-05	0.0198	CbGeAlD
Valsartan—CYP2C9—blood—coronary artery disease	5.21e-05	0.0156	CbGeAlD
Valsartan—Losartan—AGTR1—coronary artery disease	5.12e-05	0.0628	CrCbGaD
Valsartan—Losartan—ACE—coronary artery disease	2.96e-05	0.0363	CrCbGaD
Valsartan—Losartan—CYP2C19—coronary artery disease	2.19e-05	0.0268	CrCbGaD
Valsartan—Dizziness—Eplerenone—coronary artery disease	1.24e-05	0.000355	CcSEcCtD
Valsartan—Rash—Clopidogrel—coronary artery disease	1.24e-05	0.000355	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Ramipril—coronary artery disease	1.24e-05	0.000355	CcSEcCtD
Valsartan—Dermatitis—Clopidogrel—coronary artery disease	1.24e-05	0.000355	CcSEcCtD
Valsartan—Constipation—Furosemide—coronary artery disease	1.24e-05	0.000354	CcSEcCtD
Valsartan—Hypersensitivity—Niacin—coronary artery disease	1.23e-05	0.000354	CcSEcCtD
Valsartan—Asthenia—Olmesartan—coronary artery disease	1.23e-05	0.000353	CcSEcCtD
Valsartan—Headache—Clopidogrel—coronary artery disease	1.23e-05	0.000353	CcSEcCtD
Valsartan—Rash—Lovastatin—coronary artery disease	1.23e-05	0.000353	CcSEcCtD
Valsartan—Dermatitis—Lovastatin—coronary artery disease	1.23e-05	0.000353	CcSEcCtD
Valsartan—Dyspepsia—Losartan—coronary artery disease	1.23e-05	0.000352	CcSEcCtD
Valsartan—Headache—Lovastatin—coronary artery disease	1.22e-05	0.000351	CcSEcCtD
Valsartan—Dry mouth—Ramipril—coronary artery disease	1.22e-05	0.00035	CcSEcCtD
Valsartan—Myalgia—Timolol—coronary artery disease	1.22e-05	0.00035	CcSEcCtD
Valsartan—Chest pain—Timolol—coronary artery disease	1.22e-05	0.00035	CcSEcCtD
Valsartan—Arthralgia—Timolol—coronary artery disease	1.22e-05	0.00035	CcSEcCtD
Valsartan—Vomiting—Ezetimibe—coronary artery disease	1.22e-05	0.000349	CcSEcCtD
Valsartan—Hypersensitivity—Pravastatin—coronary artery disease	1.22e-05	0.000349	CcSEcCtD
Valsartan—Gastrointestinal pain—Perindopril—coronary artery disease	1.21e-05	0.000349	CcSEcCtD
Valsartan—Anxiety—Timolol—coronary artery disease	1.21e-05	0.000348	CcSEcCtD
Valsartan—Angioedema—Lisinopril—coronary artery disease	1.21e-05	0.000348	CcSEcCtD
Valsartan—Pruritus—Olmesartan—coronary artery disease	1.21e-05	0.000348	CcSEcCtD
Valsartan—Losartan—ALB—coronary artery disease	1.21e-05	0.0149	CrCbGaD
Valsartan—Decreased appetite—Losartan—coronary artery disease	1.21e-05	0.000348	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Timolol—coronary artery disease	1.21e-05	0.000347	CcSEcCtD
Valsartan—Abdominal pain—Captopril—coronary artery disease	1.21e-05	0.000347	CcSEcCtD
Valsartan—Dizziness—Simvastatin—coronary artery disease	1.21e-05	0.000346	CcSEcCtD
Valsartan—Rash—Ezetimibe—coronary artery disease	1.21e-05	0.000346	CcSEcCtD
Valsartan—Dermatitis—Ezetimibe—coronary artery disease	1.21e-05	0.000346	CcSEcCtD
Valsartan—Asthenia—Niacin—coronary artery disease	1.2e-05	0.000345	CcSEcCtD
Valsartan—Fatigue—Losartan—coronary artery disease	1.2e-05	0.000345	CcSEcCtD
Valsartan—Headache—Ezetimibe—coronary artery disease	1.2e-05	0.000344	CcSEcCtD
Valsartan—Oedema—Ramipril—coronary artery disease	1.19e-05	0.000343	CcSEcCtD
Valsartan—Anaphylactic shock—Ramipril—coronary artery disease	1.19e-05	0.000343	CcSEcCtD
Valsartan—Vertigo—Lisinopril—coronary artery disease	1.19e-05	0.000342	CcSEcCtD
Valsartan—Dry mouth—Timolol—coronary artery disease	1.19e-05	0.000342	CcSEcCtD
Valsartan—Constipation—Losartan—coronary artery disease	1.19e-05	0.000342	CcSEcCtD
Valsartan—Syncope—Lisinopril—coronary artery disease	1.19e-05	0.000342	CcSEcCtD
Valsartan—Vomiting—Eplerenone—coronary artery disease	1.19e-05	0.000342	CcSEcCtD
Valsartan—Nausea—Fenofibrate—coronary artery disease	1.19e-05	0.000341	CcSEcCtD
Valsartan—Pruritus—Niacin—coronary artery disease	1.19e-05	0.00034	CcSEcCtD
Valsartan—Asthenia—Pravastatin—coronary artery disease	1.18e-05	0.00034	CcSEcCtD
Valsartan—Gastrointestinal pain—Furosemide—coronary artery disease	1.18e-05	0.000339	CcSEcCtD
Valsartan—Rash—Eplerenone—coronary artery disease	1.18e-05	0.000339	CcSEcCtD
Valsartan—Urticaria—Perindopril—coronary artery disease	1.18e-05	0.000339	CcSEcCtD
Valsartan—Hypersensitivity—Trandolapril—coronary artery disease	1.18e-05	0.000339	CcSEcCtD
Valsartan—Dermatitis—Eplerenone—coronary artery disease	1.18e-05	0.000339	CcSEcCtD
Valsartan—Shock—Ramipril—coronary artery disease	1.18e-05	0.000337	CcSEcCtD
Valsartan—Hypersensitivity—Enalapril—coronary artery disease	1.18e-05	0.000337	CcSEcCtD
Valsartan—Abdominal pain—Perindopril—coronary artery disease	1.17e-05	0.000337	CcSEcCtD
Valsartan—Palpitations—Lisinopril—coronary artery disease	1.17e-05	0.000337	CcSEcCtD
Valsartan—Diarrhoea—Olmesartan—coronary artery disease	1.17e-05	0.000337	CcSEcCtD
Valsartan—Headache—Eplerenone—coronary artery disease	1.17e-05	0.000337	CcSEcCtD
Valsartan—Nervous system disorder—Ramipril—coronary artery disease	1.17e-05	0.000336	CcSEcCtD
Valsartan—Thrombocytopenia—Ramipril—coronary artery disease	1.17e-05	0.000336	CcSEcCtD
Valsartan—Oedema—Timolol—coronary artery disease	1.17e-05	0.000335	CcSEcCtD
Valsartan—Anaphylactic shock—Timolol—coronary artery disease	1.17e-05	0.000335	CcSEcCtD
Valsartan—Pruritus—Pravastatin—coronary artery disease	1.17e-05	0.000335	CcSEcCtD
Valsartan—Loss of consciousness—Lisinopril—coronary artery disease	1.17e-05	0.000335	CcSEcCtD
Valsartan—Nausea—Clopidogrel—coronary artery disease	1.17e-05	0.000335	CcSEcCtD
Valsartan—Skin disorder—Ramipril—coronary artery disease	1.16e-05	0.000333	CcSEcCtD
Valsartan—Infection—Timolol—coronary artery disease	1.16e-05	0.000333	CcSEcCtD
Valsartan—Vomiting—Simvastatin—coronary artery disease	1.16e-05	0.000333	CcSEcCtD
Valsartan—Hypersensitivity—Telmisartan—coronary artery disease	1.16e-05	0.000333	CcSEcCtD
Valsartan—Cough—Lisinopril—coronary artery disease	1.16e-05	0.000332	CcSEcCtD
Valsartan—Nausea—Lovastatin—coronary artery disease	1.16e-05	0.000332	CcSEcCtD
Valsartan—Rash—Simvastatin—coronary artery disease	1.15e-05	0.00033	CcSEcCtD
Valsartan—Dermatitis—Simvastatin—coronary artery disease	1.15e-05	0.00033	CcSEcCtD
Valsartan—Asthenia—Trandolapril—coronary artery disease	1.15e-05	0.00033	CcSEcCtD
Valsartan—Shock—Timolol—coronary artery disease	1.15e-05	0.00033	CcSEcCtD
Valsartan—Urticaria—Furosemide—coronary artery disease	1.15e-05	0.000329	CcSEcCtD
Valsartan—Diarrhoea—Niacin—coronary artery disease	1.15e-05	0.000329	CcSEcCtD
Valsartan—Nervous system disorder—Timolol—coronary artery disease	1.15e-05	0.000329	CcSEcCtD
Valsartan—Asthenia—Enalapril—coronary artery disease	1.14e-05	0.000328	CcSEcCtD
Valsartan—Headache—Simvastatin—coronary artery disease	1.14e-05	0.000328	CcSEcCtD
Valsartan—Abdominal pain—Furosemide—coronary artery disease	1.14e-05	0.000328	CcSEcCtD
Valsartan—Gastrointestinal pain—Losartan—coronary artery disease	1.14e-05	0.000327	CcSEcCtD
Valsartan—Anorexia—Ramipril—coronary artery disease	1.14e-05	0.000327	CcSEcCtD
Valsartan—Nausea—Ezetimibe—coronary artery disease	1.14e-05	0.000326	CcSEcCtD
Valsartan—Skin disorder—Timolol—coronary artery disease	1.13e-05	0.000326	CcSEcCtD
Valsartan—Dizziness—Olmesartan—coronary artery disease	1.13e-05	0.000325	CcSEcCtD
Valsartan—Pruritus—Trandolapril—coronary artery disease	1.13e-05	0.000325	CcSEcCtD
Valsartan—Arthralgia—Lisinopril—coronary artery disease	1.13e-05	0.000324	CcSEcCtD
Valsartan—Chest pain—Lisinopril—coronary artery disease	1.13e-05	0.000324	CcSEcCtD
Valsartan—Myalgia—Lisinopril—coronary artery disease	1.13e-05	0.000324	CcSEcCtD
Valsartan—Asthenia—Telmisartan—coronary artery disease	1.13e-05	0.000324	CcSEcCtD
Valsartan—Pruritus—Enalapril—coronary artery disease	1.13e-05	0.000324	CcSEcCtD
Valsartan—Diarrhoea—Pravastatin—coronary artery disease	1.13e-05	0.000324	CcSEcCtD
Valsartan—Anxiety—Lisinopril—coronary artery disease	1.13e-05	0.000323	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—coronary artery disease	1.12e-05	0.000322	CcSEcCtD
Valsartan—Hypotension—Ramipril—coronary artery disease	1.12e-05	0.00032	CcSEcCtD
Valsartan—Anorexia—Timolol—coronary artery disease	1.11e-05	0.00032	CcSEcCtD
Valsartan—Pruritus—Telmisartan—coronary artery disease	1.11e-05	0.000319	CcSEcCtD
Valsartan—Nausea—Eplerenone—coronary artery disease	1.11e-05	0.000319	CcSEcCtD
Valsartan—Dizziness—Niacin—coronary artery disease	1.11e-05	0.000318	CcSEcCtD
Valsartan—Urticaria—Losartan—coronary artery disease	1.11e-05	0.000318	CcSEcCtD
Valsartan—Dry mouth—Lisinopril—coronary artery disease	1.11e-05	0.000317	CcSEcCtD
Valsartan—Abdominal pain—Losartan—coronary artery disease	1.1e-05	0.000316	CcSEcCtD
Valsartan—Asthenia—Captopril—coronary artery disease	1.1e-05	0.000315	CcSEcCtD
Valsartan—Diarrhoea—Trandolapril—coronary artery disease	1.1e-05	0.000315	CcSEcCtD
Valsartan—Diarrhoea—Enalapril—coronary artery disease	1.09e-05	0.000313	CcSEcCtD
Valsartan—Hypotension—Timolol—coronary artery disease	1.09e-05	0.000313	CcSEcCtD
Valsartan—Dizziness—Pravastatin—coronary artery disease	1.09e-05	0.000313	CcSEcCtD
Valsartan—Vomiting—Olmesartan—coronary artery disease	1.09e-05	0.000313	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Ramipril—coronary artery disease	1.09e-05	0.000312	CcSEcCtD
Valsartan—Nausea—Simvastatin—coronary artery disease	1.08e-05	0.000311	CcSEcCtD
Valsartan—Oedema—Lisinopril—coronary artery disease	1.08e-05	0.000311	CcSEcCtD
Valsartan—Anaphylactic shock—Lisinopril—coronary artery disease	1.08e-05	0.000311	CcSEcCtD
Valsartan—Pruritus—Captopril—coronary artery disease	1.08e-05	0.000311	CcSEcCtD
Valsartan—Rash—Olmesartan—coronary artery disease	1.08e-05	0.00031	CcSEcCtD
Valsartan—Insomnia—Ramipril—coronary artery disease	1.08e-05	0.00031	CcSEcCtD
Valsartan—Dermatitis—Olmesartan—coronary artery disease	1.08e-05	0.00031	CcSEcCtD
Valsartan—Diarrhoea—Telmisartan—coronary artery disease	1.08e-05	0.000309	CcSEcCtD
Valsartan—Infection—Lisinopril—coronary artery disease	1.08e-05	0.000309	CcSEcCtD
Valsartan—Headache—Olmesartan—coronary artery disease	1.07e-05	0.000308	CcSEcCtD
Valsartan—Paraesthesia—Ramipril—coronary artery disease	1.07e-05	0.000308	CcSEcCtD
Valsartan—Shock—Lisinopril—coronary artery disease	1.07e-05	0.000306	CcSEcCtD
Valsartan—Asthenia—Perindopril—coronary artery disease	1.07e-05	0.000306	CcSEcCtD
Valsartan—Dyspnoea—Ramipril—coronary artery disease	1.07e-05	0.000306	CcSEcCtD
Valsartan—Vomiting—Niacin—coronary artery disease	1.07e-05	0.000306	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Timolol—coronary artery disease	1.06e-05	0.000305	CcSEcCtD
Valsartan—Hypersensitivity—Furosemide—coronary artery disease	1.06e-05	0.000305	CcSEcCtD
Valsartan—Somnolence—Ramipril—coronary artery disease	1.06e-05	0.000305	CcSEcCtD
Valsartan—Thrombocytopenia—Lisinopril—coronary artery disease	1.06e-05	0.000304	CcSEcCtD
Valsartan—Dizziness—Trandolapril—coronary artery disease	1.06e-05	0.000304	CcSEcCtD
Valsartan—Insomnia—Timolol—coronary artery disease	1.06e-05	0.000303	CcSEcCtD
Valsartan—Rash—Niacin—coronary artery disease	1.06e-05	0.000303	CcSEcCtD
Valsartan—Dermatitis—Niacin—coronary artery disease	1.06e-05	0.000303	CcSEcCtD
Valsartan—Dizziness—Enalapril—coronary artery disease	1.06e-05	0.000303	CcSEcCtD
Valsartan—Skin disorder—Lisinopril—coronary artery disease	1.05e-05	0.000302	CcSEcCtD
Valsartan—Dyspepsia—Ramipril—coronary artery disease	1.05e-05	0.000302	CcSEcCtD
Valsartan—Pruritus—Perindopril—coronary artery disease	1.05e-05	0.000302	CcSEcCtD
Valsartan—Headache—Niacin—coronary artery disease	1.05e-05	0.000301	CcSEcCtD
Valsartan—Paraesthesia—Timolol—coronary artery disease	1.05e-05	0.000301	CcSEcCtD
Valsartan—Vomiting—Pravastatin—coronary artery disease	1.05e-05	0.000301	CcSEcCtD
Valsartan—Diarrhoea—Captopril—coronary artery disease	1.05e-05	0.0003	CcSEcCtD
Valsartan—Dyspnoea—Timolol—coronary artery disease	1.04e-05	0.000299	CcSEcCtD
Valsartan—Dizziness—Telmisartan—coronary artery disease	1.04e-05	0.000299	CcSEcCtD
Valsartan—Rash—Pravastatin—coronary artery disease	1.04e-05	0.000298	CcSEcCtD
Valsartan—Dermatitis—Pravastatin—coronary artery disease	1.04e-05	0.000298	CcSEcCtD
Valsartan—Decreased appetite—Ramipril—coronary artery disease	1.04e-05	0.000298	CcSEcCtD
Valsartan—Somnolence—Timolol—coronary artery disease	1.04e-05	0.000298	CcSEcCtD
Valsartan—Asthenia—Furosemide—coronary artery disease	1.04e-05	0.000297	CcSEcCtD
Valsartan—Headache—Pravastatin—coronary artery disease	1.03e-05	0.000297	CcSEcCtD
Valsartan—Anorexia—Lisinopril—coronary artery disease	1.03e-05	0.000296	CcSEcCtD
Valsartan—Gastrointestinal disorder—Ramipril—coronary artery disease	1.03e-05	0.000296	CcSEcCtD
Valsartan—Fatigue—Ramipril—coronary artery disease	1.03e-05	0.000296	CcSEcCtD
Valsartan—Dyspepsia—Timolol—coronary artery disease	1.03e-05	0.000295	CcSEcCtD
Valsartan—Hypersensitivity—Losartan—coronary artery disease	1.03e-05	0.000295	CcSEcCtD
Valsartan—Pruritus—Furosemide—coronary artery disease	1.02e-05	0.000293	CcSEcCtD
Valsartan—Constipation—Ramipril—coronary artery disease	1.02e-05	0.000293	CcSEcCtD
Valsartan—Nausea—Olmesartan—coronary artery disease	1.02e-05	0.000292	CcSEcCtD
Valsartan—Vomiting—Trandolapril—coronary artery disease	1.02e-05	0.000292	CcSEcCtD
Valsartan—Diarrhoea—Perindopril—coronary artery disease	1.02e-05	0.000292	CcSEcCtD
Valsartan—Decreased appetite—Timolol—coronary artery disease	1.02e-05	0.000291	CcSEcCtD
Valsartan—Vomiting—Enalapril—coronary artery disease	1.01e-05	0.000291	CcSEcCtD
Valsartan—Hypotension—Lisinopril—coronary artery disease	1.01e-05	0.000291	CcSEcCtD
Valsartan—Dizziness—Captopril—coronary artery disease	1.01e-05	0.00029	CcSEcCtD
Valsartan—Rash—Trandolapril—coronary artery disease	1.01e-05	0.00029	CcSEcCtD
Valsartan—Dermatitis—Trandolapril—coronary artery disease	1.01e-05	0.00029	CcSEcCtD
Valsartan—Gastrointestinal disorder—Timolol—coronary artery disease	1.01e-05	0.000289	CcSEcCtD
Valsartan—Fatigue—Timolol—coronary artery disease	1.01e-05	0.000289	CcSEcCtD
Valsartan—Rash—Enalapril—coronary artery disease	1.01e-05	0.000289	CcSEcCtD
Valsartan—Dermatitis—Enalapril—coronary artery disease	1.01e-05	0.000288	CcSEcCtD
Valsartan—Headache—Trandolapril—coronary artery disease	1e-05	0.000288	CcSEcCtD
Valsartan—Vomiting—Telmisartan—coronary artery disease	1e-05	0.000287	CcSEcCtD
Valsartan—Asthenia—Losartan—coronary artery disease	1e-05	0.000287	CcSEcCtD
Valsartan—Headache—Enalapril—coronary artery disease	9.99e-06	0.000287	CcSEcCtD
Valsartan—Nausea—Niacin—coronary artery disease	9.95e-06	0.000286	CcSEcCtD
Valsartan—Rash—Telmisartan—coronary artery disease	9.92e-06	0.000285	CcSEcCtD
Valsartan—Dermatitis—Telmisartan—coronary artery disease	9.91e-06	0.000284	CcSEcCtD
Valsartan—Diarrhoea—Furosemide—coronary artery disease	9.88e-06	0.000284	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Lisinopril—coronary artery disease	9.87e-06	0.000283	CcSEcCtD
Valsartan—Pruritus—Losartan—coronary artery disease	9.86e-06	0.000283	CcSEcCtD
Valsartan—Headache—Telmisartan—coronary artery disease	9.86e-06	0.000283	CcSEcCtD
Valsartan—Dizziness—Perindopril—coronary artery disease	9.82e-06	0.000282	CcSEcCtD
Valsartan—Insomnia—Lisinopril—coronary artery disease	9.8e-06	0.000281	CcSEcCtD
Valsartan—Nausea—Pravastatin—coronary artery disease	9.8e-06	0.000281	CcSEcCtD
Valsartan—Gastrointestinal pain—Ramipril—coronary artery disease	9.77e-06	0.00028	CcSEcCtD
Valsartan—Paraesthesia—Lisinopril—coronary artery disease	9.73e-06	0.000279	CcSEcCtD
Valsartan—Vomiting—Captopril—coronary artery disease	9.73e-06	0.000279	CcSEcCtD
Valsartan—Dyspnoea—Lisinopril—coronary artery disease	9.66e-06	0.000277	CcSEcCtD
Valsartan—Rash—Captopril—coronary artery disease	9.65e-06	0.000277	CcSEcCtD
Valsartan—Dermatitis—Captopril—coronary artery disease	9.64e-06	0.000277	CcSEcCtD
Valsartan—Somnolence—Lisinopril—coronary artery disease	9.63e-06	0.000276	CcSEcCtD
Valsartan—Headache—Captopril—coronary artery disease	9.59e-06	0.000275	CcSEcCtD
Valsartan—Gastrointestinal pain—Timolol—coronary artery disease	9.55e-06	0.000274	CcSEcCtD
Valsartan—Dizziness—Furosemide—coronary artery disease	9.55e-06	0.000274	CcSEcCtD
Valsartan—Dyspepsia—Lisinopril—coronary artery disease	9.54e-06	0.000274	CcSEcCtD
Valsartan—Diarrhoea—Losartan—coronary artery disease	9.53e-06	0.000274	CcSEcCtD
Valsartan—Nausea—Trandolapril—coronary artery disease	9.51e-06	0.000273	CcSEcCtD
Valsartan—Urticaria—Ramipril—coronary artery disease	9.49e-06	0.000272	CcSEcCtD
Valsartan—Nausea—Enalapril—coronary artery disease	9.48e-06	0.000272	CcSEcCtD
Valsartan—Vomiting—Perindopril—coronary artery disease	9.45e-06	0.000271	CcSEcCtD
Valsartan—Abdominal pain—Ramipril—coronary artery disease	9.45e-06	0.000271	CcSEcCtD
Valsartan—Decreased appetite—Lisinopril—coronary artery disease	9.42e-06	0.00027	CcSEcCtD
Valsartan—Rash—Perindopril—coronary artery disease	9.37e-06	0.000269	CcSEcCtD
Valsartan—Dermatitis—Perindopril—coronary artery disease	9.36e-06	0.000269	CcSEcCtD
Valsartan—Gastrointestinal disorder—Lisinopril—coronary artery disease	9.36e-06	0.000268	CcSEcCtD
Valsartan—Nausea—Telmisartan—coronary artery disease	9.35e-06	0.000268	CcSEcCtD
Valsartan—Fatigue—Lisinopril—coronary artery disease	9.34e-06	0.000268	CcSEcCtD
Valsartan—Headache—Perindopril—coronary artery disease	9.31e-06	0.000267	CcSEcCtD
Valsartan—Urticaria—Timolol—coronary artery disease	9.28e-06	0.000266	CcSEcCtD
Valsartan—Constipation—Lisinopril—coronary artery disease	9.27e-06	0.000266	CcSEcCtD
Valsartan—Abdominal pain—Timolol—coronary artery disease	9.23e-06	0.000265	CcSEcCtD
Valsartan—Dizziness—Losartan—coronary artery disease	9.21e-06	0.000264	CcSEcCtD
Valsartan—Vomiting—Furosemide—coronary artery disease	9.18e-06	0.000264	CcSEcCtD
Valsartan—Rash—Furosemide—coronary artery disease	9.11e-06	0.000261	CcSEcCtD
Valsartan—Dermatitis—Furosemide—coronary artery disease	9.1e-06	0.000261	CcSEcCtD
Valsartan—Nausea—Captopril—coronary artery disease	9.09e-06	0.000261	CcSEcCtD
Valsartan—Headache—Furosemide—coronary artery disease	9.05e-06	0.00026	CcSEcCtD
Valsartan—Gastrointestinal pain—Lisinopril—coronary artery disease	8.86e-06	0.000254	CcSEcCtD
Valsartan—Vomiting—Losartan—coronary artery disease	8.86e-06	0.000254	CcSEcCtD
Valsartan—Nausea—Perindopril—coronary artery disease	8.82e-06	0.000253	CcSEcCtD
Valsartan—Hypersensitivity—Ramipril—coronary artery disease	8.8e-06	0.000253	CcSEcCtD
Valsartan—Rash—Losartan—coronary artery disease	8.79e-06	0.000252	CcSEcCtD
Valsartan—Dermatitis—Losartan—coronary artery disease	8.78e-06	0.000252	CcSEcCtD
Valsartan—Headache—Losartan—coronary artery disease	8.73e-06	0.000251	CcSEcCtD
Valsartan—Urticaria—Lisinopril—coronary artery disease	8.61e-06	0.000247	CcSEcCtD
Valsartan—Hypersensitivity—Timolol—coronary artery disease	8.61e-06	0.000247	CcSEcCtD
Valsartan—Nausea—Furosemide—coronary artery disease	8.58e-06	0.000246	CcSEcCtD
Valsartan—Asthenia—Ramipril—coronary artery disease	8.57e-06	0.000246	CcSEcCtD
Valsartan—Abdominal pain—Lisinopril—coronary artery disease	8.57e-06	0.000246	CcSEcCtD
Valsartan—Pruritus—Ramipril—coronary artery disease	8.45e-06	0.000243	CcSEcCtD
Valsartan—Asthenia—Timolol—coronary artery disease	8.38e-06	0.000241	CcSEcCtD
Valsartan—Nausea—Losartan—coronary artery disease	8.28e-06	0.000238	CcSEcCtD
Valsartan—Pruritus—Timolol—coronary artery disease	8.26e-06	0.000237	CcSEcCtD
Valsartan—Diarrhoea—Ramipril—coronary artery disease	8.18e-06	0.000235	CcSEcCtD
Valsartan—Diarrhoea—Timolol—coronary artery disease	7.99e-06	0.000229	CcSEcCtD
Valsartan—Hypersensitivity—Lisinopril—coronary artery disease	7.98e-06	0.000229	CcSEcCtD
Valsartan—Dizziness—Ramipril—coronary artery disease	7.9e-06	0.000227	CcSEcCtD
Valsartan—Asthenia—Lisinopril—coronary artery disease	7.77e-06	0.000223	CcSEcCtD
Valsartan—Dizziness—Timolol—coronary artery disease	7.72e-06	0.000222	CcSEcCtD
Valsartan—Pruritus—Lisinopril—coronary artery disease	7.67e-06	0.00022	CcSEcCtD
Valsartan—Vomiting—Ramipril—coronary artery disease	7.6e-06	0.000218	CcSEcCtD
Valsartan—Rash—Ramipril—coronary artery disease	7.53e-06	0.000216	CcSEcCtD
Valsartan—Dermatitis—Ramipril—coronary artery disease	7.53e-06	0.000216	CcSEcCtD
Valsartan—Headache—Ramipril—coronary artery disease	7.49e-06	0.000215	CcSEcCtD
Valsartan—Vomiting—Timolol—coronary artery disease	7.43e-06	0.000213	CcSEcCtD
Valsartan—Diarrhoea—Lisinopril—coronary artery disease	7.41e-06	0.000213	CcSEcCtD
Valsartan—Rash—Timolol—coronary artery disease	7.37e-06	0.000211	CcSEcCtD
Valsartan—Dermatitis—Timolol—coronary artery disease	7.36e-06	0.000211	CcSEcCtD
Valsartan—Headache—Timolol—coronary artery disease	7.32e-06	0.00021	CcSEcCtD
Valsartan—Dizziness—Lisinopril—coronary artery disease	7.17e-06	0.000206	CcSEcCtD
Valsartan—Nausea—Ramipril—coronary artery disease	7.1e-06	0.000204	CcSEcCtD
Valsartan—Nausea—Timolol—coronary artery disease	6.94e-06	0.000199	CcSEcCtD
Valsartan—Vomiting—Lisinopril—coronary artery disease	6.89e-06	0.000198	CcSEcCtD
Valsartan—Rash—Lisinopril—coronary artery disease	6.83e-06	0.000196	CcSEcCtD
Valsartan—Dermatitis—Lisinopril—coronary artery disease	6.83e-06	0.000196	CcSEcCtD
Valsartan—Headache—Lisinopril—coronary artery disease	6.79e-06	0.000195	CcSEcCtD
Valsartan—Nausea—Lisinopril—coronary artery disease	6.44e-06	0.000185	CcSEcCtD
Valsartan—ALB—Transmembrane transport of small molecules—APOB—coronary artery disease	1.71e-06	0.000109	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ABCA1—coronary artery disease	1.7e-06	0.000109	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AGT—coronary artery disease	1.7e-06	0.000109	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HK2—coronary artery disease	1.7e-06	0.000109	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AKR1B1—coronary artery disease	1.7e-06	0.000109	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—GPX1—coronary artery disease	1.67e-06	0.000107	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—APOE—coronary artery disease	1.67e-06	0.000106	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—VEGFA—coronary artery disease	1.65e-06	0.000106	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOA2—coronary artery disease	1.65e-06	0.000105	CbGpPWpGaD
Valsartan—ALB—Metabolism—GPX2—coronary artery disease	1.65e-06	0.000105	CbGpPWpGaD
Valsartan—ALB—Metabolism—PLA2G2A—coronary artery disease	1.65e-06	0.000105	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GGT1—coronary artery disease	1.65e-06	0.000105	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GOT1—coronary artery disease	1.65e-06	0.000105	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—APOA1—coronary artery disease	1.65e-06	0.000105	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HIF1A—coronary artery disease	1.64e-06	0.000105	CbGpPWpGaD
Valsartan—ALB—Hemostasis—MMP1—coronary artery disease	1.63e-06	0.000104	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC27A1—coronary artery disease	1.63e-06	0.000104	CbGpPWpGaD
Valsartan—ALB—Metabolism—HK1—coronary artery disease	1.63e-06	0.000104	CbGpPWpGaD
Valsartan—ALB—Metabolism—GPX4—coronary artery disease	1.63e-06	0.000104	CbGpPWpGaD
Valsartan—ALB—Metabolism—ABCG5—coronary artery disease	1.63e-06	0.000104	CbGpPWpGaD
Valsartan—ALB—Metabolism—SULT1A1—coronary artery disease	1.63e-06	0.000104	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AGT—coronary artery disease	1.63e-06	0.000104	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CD36—coronary artery disease	1.63e-06	0.000104	CbGpPWpGaD
Valsartan—ALB—Metabolism—HADHA—coronary artery disease	1.61e-06	0.000103	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PLAU—coronary artery disease	1.6e-06	0.000102	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CPT1B—coronary artery disease	1.6e-06	0.000102	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LCAT—coronary artery disease	1.6e-06	0.000102	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APOE—coronary artery disease	1.6e-06	0.000102	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—LEP—coronary artery disease	1.6e-06	0.000102	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTA1—coronary artery disease	1.59e-06	0.000102	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APOA1—coronary artery disease	1.58e-06	0.000101	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	1.58e-06	0.000101	CbGpPWpGaD
Valsartan—ALB—Metabolism—LPA—coronary artery disease	1.57e-06	0.000101	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOA4—coronary artery disease	1.57e-06	0.0001	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KDR—coronary artery disease	1.56e-06	0.0001	CbGpPWpGaD
Valsartan—ALB—Hemostasis—APOA1—coronary artery disease	1.56e-06	9.97e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MAPK14—coronary artery disease	1.55e-06	9.93e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARGC1A—coronary artery disease	1.54e-06	9.84e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—MAPK14—coronary artery disease	1.53e-06	9.81e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PLCB3—coronary artery disease	1.52e-06	9.74e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ESR1—coronary artery disease	1.52e-06	9.74e-05	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—TGFB1—coronary artery disease	1.52e-06	9.69e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PDHA1—coronary artery disease	1.51e-06	9.68e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GCLM—coronary artery disease	1.51e-06	9.68e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOA5—coronary artery disease	1.51e-06	9.64e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—F2—coronary artery disease	1.51e-06	9.62e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FN1—coronary artery disease	1.51e-06	9.62e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6ST—coronary artery disease	1.5e-06	9.58e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NFKBIA—coronary artery disease	1.49e-06	9.51e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—FN1—coronary artery disease	1.49e-06	9.51e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—F2—coronary artery disease	1.49e-06	9.51e-05	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—MAPK1—coronary artery disease	1.49e-06	9.5e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTP1—coronary artery disease	1.48e-06	9.46e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—P4HB—coronary artery disease	1.48e-06	9.46e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NOS2—coronary artery disease	1.47e-06	9.39e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOB—coronary artery disease	1.47e-06	9.39e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TXNRD1—coronary artery disease	1.47e-06	9.38e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP11B2—coronary artery disease	1.47e-06	9.38e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARGC1A—coronary artery disease	1.47e-06	9.37e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—AGT—coronary artery disease	1.47e-06	9.37e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—HMOX1—coronary artery disease	1.46e-06	9.33e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PLA2G1B—coronary artery disease	1.45e-06	9.28e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PPARG—coronary artery disease	1.45e-06	9.27e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC22A3—coronary artery disease	1.44e-06	9.24e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KIT—coronary artery disease	1.44e-06	9.21e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CAT—coronary artery disease	1.44e-06	9.21e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—APOE—coronary artery disease	1.44e-06	9.18e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—POMC—coronary artery disease	1.43e-06	9.15e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ARNTL—coronary artery disease	1.42e-06	9.1e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HADH—coronary artery disease	1.42e-06	9.1e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—APOA1—coronary artery disease	1.42e-06	9.07e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—LPL—coronary artery disease	1.4e-06	8.96e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOB—coronary artery disease	1.4e-06	8.94e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—GSK3B—coronary artery disease	1.38e-06	8.84e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—POMC—coronary artery disease	1.37e-06	8.77e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CREB1—coronary artery disease	1.37e-06	8.77e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—VCAN—coronary artery disease	1.37e-06	8.75e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—coronary artery disease	1.37e-06	8.74e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTM1—coronary artery disease	1.36e-06	8.69e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—ALDOA—coronary artery disease	1.36e-06	8.68e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOA2—coronary artery disease	1.35e-06	8.63e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PLA2G2A—coronary artery disease	1.35e-06	8.63e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GPX2—coronary artery disease	1.35e-06	8.63e-05	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—APOA1—coronary artery disease	1.35e-06	8.63e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL2—coronary artery disease	1.34e-06	8.58e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6R—coronary artery disease	1.34e-06	8.55e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—LPL—coronary artery disease	1.34e-06	8.53e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HK1—coronary artery disease	1.33e-06	8.52e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCG5—coronary artery disease	1.33e-06	8.52e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SULT1A1—coronary artery disease	1.33e-06	8.52e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GPX4—coronary artery disease	1.33e-06	8.52e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CD36—coronary artery disease	1.33e-06	8.52e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IGF1—coronary artery disease	1.32e-06	8.43e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—DCN—coronary artery disease	1.32e-06	8.43e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HADHA—coronary artery disease	1.32e-06	8.42e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—MAPK1—coronary artery disease	1.31e-06	8.39e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ALB—coronary artery disease	1.3e-06	8.34e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—IGF1—coronary artery disease	1.3e-06	8.33e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GPX1—coronary artery disease	1.3e-06	8.33e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTA1—coronary artery disease	1.3e-06	8.33e-05	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PIK3CA—coronary artery disease	1.29e-06	8.24e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LPA—coronary artery disease	1.29e-06	8.23e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—ALDH2—coronary artery disease	1.28e-06	8.2e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CD36—coronary artery disease	1.27e-06	8.11e-05	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PIK3CA—coronary artery disease	1.25e-06	8.02e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPP2CA—coronary artery disease	1.25e-06	8.01e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SERPINE1—coronary artery disease	1.25e-06	8.01e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PPARG—coronary artery disease	1.25e-06	7.99e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—LIPC—coronary artery disease	1.25e-06	7.99e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3C2A—coronary artery disease	1.25e-06	7.99e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—HBA1—coronary artery disease	1.25e-06	7.99e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP2C19—coronary artery disease	1.25e-06	7.99e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—NOS3—coronary artery disease	1.25e-06	7.98e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PLCB3—coronary artery disease	1.25e-06	7.97e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOC3—coronary artery disease	1.24e-06	7.94e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SERPINE1—coronary artery disease	1.24e-06	7.91e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOA5—coronary artery disease	1.23e-06	7.89e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—LDLR—coronary artery disease	1.23e-06	7.89e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—POMC—coronary artery disease	1.23e-06	7.88e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC9A1—coronary artery disease	1.22e-06	7.8e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTT1—coronary artery disease	1.22e-06	7.8e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FGF2—coronary artery disease	1.21e-06	7.75e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—P4HB—coronary artery disease	1.21e-06	7.74e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CETP—coronary artery disease	1.21e-06	7.71e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GCLC—coronary artery disease	1.21e-06	7.71e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—MTHFR—coronary artery disease	1.2e-06	7.68e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—AGT—coronary artery disease	1.2e-06	7.67e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOS3—coronary artery disease	1.2e-06	7.64e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—SDC1—coronary artery disease	1.19e-06	7.62e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PLA2G1B—coronary artery disease	1.19e-06	7.6e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NOS3—coronary artery disease	1.18e-06	7.55e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—coronary artery disease	1.18e-06	7.51e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—JAK2—coronary artery disease	1.16e-06	7.43e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—coronary artery disease	1.16e-06	7.43e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—JAK2—coronary artery disease	1.15e-06	7.34e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AGT—coronary artery disease	1.14e-06	7.3e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTGS2—coronary artery disease	1.14e-06	7.3e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PIK3CA—coronary artery disease	1.14e-06	7.28e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PSMB5—coronary artery disease	1.13e-06	7.2e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PSMA6—coronary artery disease	1.13e-06	7.2e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—VCAN—coronary artery disease	1.12e-06	7.16e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOE—coronary artery disease	1.12e-06	7.15e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALDOA—coronary artery disease	1.11e-06	7.11e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOA1—coronary artery disease	1.11e-06	7.07e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CTGF—coronary artery disease	1.1e-06	7.04e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—HMGCR—coronary artery disease	1.09e-06	6.97e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GOT2—coronary artery disease	1.09e-06	6.97e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—DCN—coronary artery disease	1.08e-06	6.9e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCL8—coronary artery disease	1.06e-06	6.78e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	1.06e-06	6.77e-05	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—AKT1—coronary artery disease	1.05e-06	6.74e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALDH2—coronary artery disease	1.05e-06	6.71e-05	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—AKT1—coronary artery disease	1.02e-06	6.55e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—coronary artery disease	1.02e-06	6.54e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LIPC—coronary artery disease	1.02e-06	6.54e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HBA1—coronary artery disease	1.02e-06	6.54e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP2C19—coronary artery disease	1.02e-06	6.54e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3C2A—coronary artery disease	1.02e-06	6.54e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOC3—coronary artery disease	1.02e-06	6.5e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CASP3—coronary artery disease	1.02e-06	6.49e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LDLR—coronary artery disease	1.01e-06	6.46e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—POMC—coronary artery disease	1.01e-06	6.45e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL6—coronary artery disease	1.01e-06	6.45e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PLCB1—coronary artery disease	1e-06	6.41e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTT1—coronary artery disease	9.99e-07	6.38e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC9A1—coronary artery disease	9.99e-07	6.38e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCND1—coronary artery disease	9.88e-07	6.32e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CETP—coronary artery disease	9.87e-07	6.31e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GCLC—coronary artery disease	9.87e-07	6.31e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTGS2—coronary artery disease	9.84e-07	6.29e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SDC1—coronary artery disease	9.76e-07	6.24e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PPARG—coronary artery disease	9.75e-07	6.23e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—ABCA1—coronary artery disease	9.72e-07	6.21e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—POMC—coronary artery disease	9.61e-07	6.15e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MMP9—coronary artery disease	9.59e-07	6.13e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GOT1—coronary artery disease	9.41e-07	6.02e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GGT1—coronary artery disease	9.41e-07	6.02e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AKT1—coronary artery disease	9.3e-07	5.95e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PSMA6—coronary artery disease	9.22e-07	5.89e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PSMB5—coronary artery disease	9.22e-07	5.89e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—coronary artery disease	9.2e-07	5.88e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CTGF—coronary artery disease	9.01e-07	5.76e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HMGCR—coronary artery disease	8.93e-07	5.71e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GOT2—coronary artery disease	8.93e-07	5.71e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ALB—coronary artery disease	8.76e-07	5.6e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—VEGFA—coronary artery disease	8.61e-07	5.51e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—VEGFA—coronary artery disease	8.51e-07	5.44e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTP1—coronary artery disease	8.46e-07	5.41e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NOS3—coronary artery disease	8.38e-07	5.36e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARGC1A—coronary artery disease	8.38e-07	5.36e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—HMOX1—coronary artery disease	8.34e-07	5.33e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CAT—coronary artery disease	8.23e-07	5.26e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PLCB1—coronary artery disease	8.21e-07	5.25e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—coronary artery disease	8.05e-07	5.15e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOB—coronary artery disease	7.99e-07	5.11e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCA1—coronary artery disease	7.96e-07	5.09e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TGFB1—coronary artery disease	7.91e-07	5.05e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TGFB1—coronary artery disease	7.81e-07	4.99e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTM1—coronary artery disease	7.77e-07	4.97e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MAPK1—coronary artery disease	7.75e-07	4.96e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GOT1—coronary artery disease	7.71e-07	4.93e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GGT1—coronary artery disease	7.71e-07	4.93e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTGS2—coronary artery disease	7.67e-07	4.9e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—MAPK1—coronary artery disease	7.66e-07	4.9e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—LPL—coronary artery disease	7.63e-07	4.88e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GPX1—coronary artery disease	7.44e-07	4.76e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CD36—coronary artery disease	7.25e-07	4.63e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPP2CA—coronary artery disease	7.16e-07	4.58e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PIK3CA—coronary artery disease	7.02e-07	4.49e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTP1—coronary artery disease	6.92e-07	4.42e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—MTHFR—coronary artery disease	6.87e-07	4.39e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARGC1A—coronary artery disease	6.86e-07	4.38e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HMOX1—coronary artery disease	6.83e-07	4.36e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CAT—coronary artery disease	6.74e-07	4.31e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PIK3CA—coronary artery disease	6.73e-07	4.3e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PIK3CA—coronary artery disease	6.65e-07	4.25e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOB—coronary artery disease	6.54e-07	4.18e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—AGT—coronary artery disease	6.53e-07	4.17e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOE—coronary artery disease	6.39e-07	4.09e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTM1—coronary artery disease	6.36e-07	4.07e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOA1—coronary artery disease	6.32e-07	4.04e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LPL—coronary artery disease	6.24e-07	3.99e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GPX1—coronary artery disease	6.09e-07	3.89e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	6.05e-07	3.87e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6—coronary artery disease	5.96e-07	3.81e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CD36—coronary artery disease	5.93e-07	3.79e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPP2CA—coronary artery disease	5.86e-07	3.74e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AKT1—coronary artery disease	5.74e-07	3.67e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MTHFR—coronary artery disease	5.62e-07	3.59e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPARG—coronary artery disease	5.57e-07	3.56e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKT1—coronary artery disease	5.5e-07	3.51e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—POMC—coronary artery disease	5.49e-07	3.51e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—AKT1—coronary artery disease	5.43e-07	3.47e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AGT—coronary artery disease	5.34e-07	3.41e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOE—coronary artery disease	5.23e-07	3.35e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOA1—coronary artery disease	5.17e-07	3.31e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—coronary artery disease	4.95e-07	3.17e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—NOS3—coronary artery disease	4.79e-07	3.06e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PIK3CA—coronary artery disease	4.72e-07	3.02e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPARG—coronary artery disease	4.56e-07	2.91e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—POMC—coronary artery disease	4.5e-07	2.87e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTGS2—coronary artery disease	4.38e-07	2.8e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALB—coronary artery disease	4.1e-07	2.62e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NOS3—coronary artery disease	3.92e-07	2.51e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AKT1—coronary artery disease	3.85e-07	2.46e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTGS2—coronary artery disease	3.59e-07	2.29e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PIK3CA—coronary artery disease	2.7e-07	1.72e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PIK3CA—coronary artery disease	2.21e-07	1.41e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—AKT1—coronary artery disease	2.2e-07	1.41e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AKT1—coronary artery disease	1.8e-07	1.15e-05	CbGpPWpGaD
